NASDAQ:SPTX Seaport Therapeutics (SPTX) Stock Price, News & Analysis $17.44 -0.56 (-3.11%) As of 06/15/2026 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Seaport Therapeutics Stock (NASDAQ:SPTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Seaport Therapeutics alerts:Sign Up Key Stats Today's Range$17.35▼$18.4550-Day Range N/A52-Week Range$14.85▼$23.00Volume104,012 shsAverage Volume278,507 shsMarket Capitalization$933.58 millionP/E RatioN/ADividend YieldN/APrice Target$35.50Consensus RatingHold Company Overview Read More Seaport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreSPTX MarketRank™: Seaport Therapeutics scored higher than 93% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSeaport Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialSeaport Therapeutics has a consensus price target of $35.50, representing about 103.6% upside from its current price of $17.44.Amount of Analyst CoverageSeaport Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Seaport Therapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.30% of the float of Seaport Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeaport Therapeutics has a short interest ratio ("days to cover") of 8.08.Change versus previous monthShort interest in Seaport Therapeutics has recently increased by 20.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeaport Therapeutics does not currently pay a dividend.Dividend GrowthSeaport Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.33 News SentimentSeaport Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Seaport Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SPTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $19,800,000.00 in company stock, which represents 2.1209% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Seaport Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,800,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsSeaport Therapeutics has minimal institutional ownership at this time.Read more about Seaport Therapeutics' insider trading history. Receive SPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seaport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPTX Stock News HeadlinesPureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgoâ„¢ in Healthy VolunteersJune 9, 2026 | businesswire.comSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressJune 8, 2026 | businesswire.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page. | Weiss Ratings (Ad)Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy VolunteersJune 8, 2026 | businesswire.comSeaport Therapeutics to Participate in Two Upcoming Investor ConferencesJune 1, 2026 | businesswire.comAssessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price MoveMay 5, 2026 | finance.yahoo.comSeaport Therapeutics Pursues IPO On Positive Trial ResultsApril 13, 2026 | seekingalpha.comSee More Headlines SPTX Stock Analysis - Frequently Asked Questions How have SPTX shares performed this year? Seaport Therapeutics' stock was trading at $19.84 at the beginning of 2026. Since then, SPTX stock has decreased by 12.1% and is now trading at $17.44. How were Seaport Therapeutics' earnings last quarter? Seaport Therapeutics, Inc. (NASDAQ:SPTX) announced its quarterly earnings data on Monday, June, 8th. The company reported ($10.34) EPS for the quarter, topping analysts' consensus estimates of ($10.64) by $0.30. When did Seaport Therapeutics IPO? Seaport Therapeutics (SPTX) raised $241 million in an initial public offering on Friday, May 1st 2026. The company issued 14,160,000 shares at $16.00-$18.00 per share. When did Seaport Therapeutics' quiet period expire? Seaport Therapeutics's quiet period expired on Wednesday, June 10th. Seaport Therapeutics had issued 14,160,000 shares in its public offering on May 1st. The total size of the offering was $254,880,000 based on an initial share price of $18.00. During Seaport Therapeutics' quiet period, insiders and underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Seaport Therapeutics? Shares of SPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/08/2026Today6/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:SPTX CIK2042347 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Seaport Therapeutics$35.50 High Price Target$42.00 Low Price Target$30.00 Potential Upside/Downside+103.6%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,531,000Free FloatN/AMarket Cap$933.58 million OptionableN/A BetaN/A 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SPTX) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...Americas Gold Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seaport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seaport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.